# Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia

**URL:** <https://forum.livingwithataxia.org/t/safety-pharmacodynamics-and-potential-benefit-of-omaveloxolone-in-friedreich-ataxia/7062>\
**Category:** General\
**Created:** [November 16, 2018, 8:39am UTC](https://forum.livingwithataxia.org/t/safety-pharmacodynamics-and-potential-benefit-of-omaveloxolone-in-friedreich-ataxia/7062 "2018-11-16T08:39:34Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Alan\_T](https://yyz1.discourse-cdn.com/flex027/user_avatar/forum.livingwithataxia.org/alan_t/32/31_2.png) [@Alan\_T](https://forum.livingwithataxia.org/u/Alan_T)\
**Post date:** [November 16, 2018, 8:39am UTC](https://forum.livingwithataxia.org/t/safety-pharmacodynamics-and-potential-benefit-of-omaveloxolone-in-friedreich-ataxia/7062/1 "2018-11-16T08:39:34Z")

</div>

### Objective

Previous studies have demonstrated that suppression of Nrf2 in Friedreich ataxia tissues contributes to excess oxidative stress, mitochondrial dysfunction, and reduced ATP production. Omaveloxolone, an Nrf2 activator and NF‐kB suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways. The dose‐ranging portion of this Phase 2 study assessed the safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia patients (NCT02255435).

[https://onlinelibrary.wiley.com/doi/10.1002/acn3.660](https://onlinelibrary.wiley.com/doi/10.1002/acn3.660)